Abstract 416P
Background
Identification of molecular subgroups has revolutionized the treatment of metastatic adenocarcinoma lung.Practice in India is to test for EGFR hotspot mutations by PCR, ALK by IHC and ROS1 by FISH (conventional testing).Tissue NGS (next generation sequencing) testing is increasing; but availability of adequate tissue is a problem.Aim of our study was to evaluate the added benefit of blood NGS testing in patients who were negative by conventional molecular testing.
Methods
This was a retrospective analysis of patients with metastatic lung cancer, who presented at Manipal hospital, Bangalore, Jan 2019 and May 2020.
Results
108 patients, 35-75 years, were analyzed. 78 (72%) men, 30(28%) women. 87 (80.6%) had adeno and 21 (19.4%) had squamous cell carcinoma. All adenocarcinoma patients were tested on tumor tissue for EGFR hotspot mutations by PCR, ALK by IHC and ROS1 by FISH. Molecular alterations by conventional testing were found in 34 (39%) patients and 53(61%) were negative. Out of these 34, 29 (33%) had EGFR, 3 (3.1%) had ALK and 2 (2.4%) had ROS1 alterations. We further evaluated the conventionally tested negative patients to blood NGS testing (liquid biopsy). Only 20 (37%) out of the 53 conventionally tested negative patients were subjected to blood NGS testing due to logistic reasons. We found 14 (70%) out of 20 had detectable mutation on blood NGS. Out of the 14, we picked up 6(42%) EGFR (3 common, 3 uncommon), 1 (7 %) ALK, 1 (7 %) ROS1, 1 (7 %) MET exon 14 skip, 2 ( 14%) HER 2 and 3 (21 %) RAS mutations (G12C). We treated 10(50%) out of 20 subjects: 5 EGFR mutation patients with geftinib/afatinib/ osimertinib, 1 ALK with crizotinib, 1 ROS with crizotinib, 1 MET with Capmatinib, and 2 HER2 with Afatinib.
Conclusions
Findings of our study proves patients who are negative by conventional testing should be further evaluated with blood NGS testing. In our study, inspite of limited testing, we were able to detect additional 14 patients with driver mutations by doing blood NGS testing, thus increasing our mutation detection from 39% to 55%.Advantage of blood NGS testing is ease of sample collection, faster turnaround time, that it is able to overcome the common problem of inadequate tissue in lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session